VivoSeq
Other

Hypotrichosis

3

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Hypotrichosis is an early-stage landscape with 3 programs across 3 companies. The most active players are Pfizer, Milestone Pharmaceuticals Inc., AbbVie. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedAbbVie logo

AbbVie

2 programs

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved3

Finasteride

Organon and Co

Minoxidil

Pfizer

Bimatoprost

AbbVie

Analysis

Trial Status

11

clinical trials

Completed10 · 91%
Active, not recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

A Pilot Clinical Trial Investigating the Effect of Autologous Platelet-rich Plasma in Subjects With Mild to Moderate Eyebrow Hypotrichosis
Active, not recruiting·NNorthwestern University·Phase 2·NCT04018859·11 enrolled
Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Completed·AbbVie logoAbbVie·N/A·NCT02505776·1,699 enrolled
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
Completed·AbbVie logoAbbVie·Phase 4·NCT00958035·89 enrolled
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Completed·AbbVie logoAbbVie·Phase 3·NCT01391286·36 enrolled
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Completed·AbbVie logoAbbVie·Phase 3·NCT01765764·357 enrolled
Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
Completed·—·Phase 4·NCT01387906·20 enrolled
Bimatoprost in the Treatment of Eyelash Hypotrichosis
Completed·AbbVie logoAbbVie·Phase 3·NCT01698554·464 enrolled
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
Completed·AbbVie logoAbbVie·Phase 4·NCT01023841·71 enrolled
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Completed·AbbVie logoAbbVie·Phase 3·NCT01391273·173 enrolled
An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
Completed·AbbVie logoAbbVie·N/A·NCT01623479·585 enrolled
Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
Completed·AbbVie logoAbbVie·Phase 3·NCT00907426·368 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)